On This Day in Health: March 18, 2022
On March 18, 2022, the United States Food and Drug Administration approved the fixed-dose combination of nivolumab and relatlimab, marketed as Opdualag, for advanced melanoma. The indication covered adults and patients aged twelve and older whose melanoma could not be removed surgically or had spread to other parts of the body. The decision introduced an approved combination targeting two immune checkpoints, PD-1 and LAG-3. It extended the history of immunotherapy for melanoma by pairing an established treatment with a new checkpoint-blocking antibody in a single intravenous product.
Immune checkpoints help regulate the activity of immune cells. In cancer treatment, blocking certain inhibitory signals can help restore an immune response against tumors. Nivolumab targets PD-1, while relatlimab targets LAG-3. The combination reflected the idea that two pathways could be addressed together, but its value still needed to be demonstrated in people. A biological rationale is a starting point for a clinical study, not a guarantee of benefit. Melanoma research had already shown the importance of immune-based treatments, and the new authorization added another approach within that developing field.
The RELATIVITY-047 trial compared the combination with nivolumab alone in 714 patients with previously untreated metastatic or unresectable melanoma. The central outcome was progression-free survival, measuring the period before disease progression or death. Median progression-free survival was approximately 10.1 months with the combination and 4.6 months with nivolumab alone. These were summaries of trial groups, not a prediction of how long an individual patient would respond. The comparison was also against an active medicine rather than placebo. That design asked whether the added checkpoint target improved a defined outcome over an existing treatment option already used in clinical practice.
The trial and prescribing framework also required attention to adverse effects, including immune-mediated problems that can affect healthy organs. Greater immune activity against a tumor does not automatically mean a treatment is easier to tolerate. March 18 therefore represents an expansion of choice supported by a comparative study, with benefit and risk assessed together. The milestone shows how progress can come from combining mechanisms within a regulated product rather than replacing an entire field of care. For the history of melanoma treatment, it marks the arrival of an authorized LAG-3-blocking component alongside PD-1 inhibition. Its lasting importance lies in bringing a new research target into clinical practice while preserving the need to evaluate outcomes, tolerability, and suitability for the people who might receive it.
The combination targeted PD-1 and LAG-3. Relatlimab added a distinct immune checkpoint to an established treatment approach.
The indication covered unresectable or metastatic melanoma in patients aged twelve and older. It was a defined advanced-disease authorization.
RELATIVITY-047 compared the combination with nivolumab alone. The study used an active treatment as its comparator.
Median progression-free survival was about 10.1 versus 4.6 months. Trial-group medians do not predict each patient's course.
Immune-mediated adverse effects remained part of the assessment. Blocking more pathways requires attention to tolerability as well as benefit.
The fixed combination was delivered as one intravenous product. The milestone connected a new research target with regulated clinical use.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.